Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | STS | P08842 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5269769 | 0.95 | CA2 (0.53) | CA2SMN1; SMN2ALDH1A1HSD17B10THRB | |
| SCHEMBL5427923 | 0.93 | CA2 (0.51) | CA2SMN1; SMN2ALDH1A1HSD17B10THRB | |
| SCHEMBL3655208 | 0.84 | CA2 (0.53) | CA2SMN1; SMN2HPGDALDH1A1HSD17B10 | |
| SCHEMBL14015390 | 0.82 | CA2 (0.51) | CA2SMN1; SMN2HPGDALDH1A1HSD17B10 | |
| SCHEMBL14063987 | 0.81 | CA2 (0.45) | CA2SMN1; SMN2HPGDALDH1A1STS | |
| SCHEMBL276788 | 0.81 | RARB (0.51) | CA2SMN1; SMN2HPGDALDH1A1HSD17B10 | |
| SCHEMBL5265636 | 0.80 | CA2 (0.56) | CA2SMN1; SMN2ALDH1A1HSD17B10THRB | |
| SCHEMBL1980097 | 0.79 | CA2 (0.49) | CA2SMN1; SMN2HPGDALDH1A1HSD17B10 | |
| SCHEMBL2829918 | 0.79 | CA2 (0.49) | CA2SMN1; SMN2HPGDALDH1A1HSD17B10 | |
| SCHEMBL10181185 | 0.79 | CA2 (0.54) | CA2SMN1; SMN2ALDH1A1HSD17B10THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070020309-A1 | Safe and effective biofilm inhibitory compounds and health related uses thereof | CUTLER, ELIOT | 2007-01-25 | — | — | US | disclosed |
| US-7087661-B1 | Safe and effective biofilm inhibitory compounds and health-related uses thereof | CERNOFINA, LLC (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1115285-A1 | SAFE AND EFFECTIVE BIOFILM INHIBITORY COMPOUNDS AND HEALTH-RELATED USES THEREOF | Phycogen, Inc. (US) | 2001-07-18 | — | — | EP | disclosed |
| EP-1115289-A2 | ENVIRONMENTALLY BENIGN CROP PROTECTION AGENTS | Phycogen, Inc. (US) | 2001-07-18 | — | — | EP | disclosed |
| EP-1115284-A1 | ANTIFOULING AGENTS | Phycogen, Inc. (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000016624-A1 | SAFE AND EFFECTIVE BIOFILM INHIBITORY COMPOUNDS AND HEALTH-RELATED USES THEREOF | PHYCOGEN, INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000016632-A2 | ENVIRONMENTALLY BENIGN CROP PROTECTION AGENTS | PHYCOGEN, INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000016623-A1 | ANTIFOULING AGENTS | PHYCOGEN, INC. (US) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070020309-A1 | Safe and effective biofilm inhibitory compounds and health related uses thereof | FGB, TFPI, F3 | CA2 2757/4885SMN1; SMN2 4792/4885HPGD 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.